Ausdal Financial Partners Inc. Invests $214,000 in Guardant Health, Inc. (NASDAQ:GH)

Ausdal Financial Partners Inc. acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 7,000 shares of the company's stock, valued at approximately $214,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. R Squared Ltd acquired a new position in shares of Guardant Health in the 4th quarter valued at about $26,000. SBI Securities Co. Ltd. bought a new stake in Guardant Health in the fourth quarter worth approximately $43,000. Kimelman & Baird LLC acquired a new position in Guardant Health in the fourth quarter valued at approximately $58,000. Quantbot Technologies LP bought a new position in shares of Guardant Health during the 4th quarter worth approximately $80,000. Finally, Jones Financial Companies Lllp grew its position in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after buying an additional 817 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GH has been the subject of several recent research reports. Piper Sandler upped their target price on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Barclays began coverage on shares of Guardant Health in a report on Thursday, January 23rd. They set an "overweight" rating and a $60.00 price objective on the stock. Stephens reiterated an "overweight" rating and set a $55.00 price objective on shares of Guardant Health in a report on Wednesday, March 26th. Canaccord Genuity Group upped their target price on shares of Guardant Health from $42.00 to $60.00 and gave the stock a "buy" rating in a report on Monday, February 24th. Finally, Stifel Nicolaus lifted their price target on Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health currently has a consensus rating of "Buy" and a consensus target price of $48.95.

Remove Ads

Guardant Health Price Performance

NASDAQ GH traded up $0.52 during trading on Wednesday, reaching $42.99. The company's stock had a trading volume of 359,322 shares, compared to its average volume of 2,330,891. The firm has a fifty day moving average of $44.72 and a 200 day moving average of $34.60. The stock has a market capitalization of $5.31 billion, a PE ratio of -12.07 and a beta of 1.50. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.